



<b>Date</b>	4 February 2008	<b>Ref</b>	08TTP03
<b>Product enquiries</b>	<b>TTP LabTech Limited – Worldwide Headquarters</b> Jas Sanghera +44 (0)1763 262626 Email: <a href="mailto:sales@ttplabtech.com">sales@ttplabtech.com</a>  <b>TTP LabTech Inc – US Office</b> Ben Schenker +1 (617) 494 9794		
<b>Media enquiries</b>	<b>Alto Marketing Limited</b> Clare Russell +44 (0)1489 557672 Email: <a href="mailto:clarer@alto-marketing.com">clarer@alto-marketing.com</a>		

## **TTP LabTech Announce Licensing of Acoustic Technology for Label-free Interaction Analysis**

**Royston, UK** – TTP LabTech today announced that it has been granted a licence for the application of Resonant Acoustic Profiling™ technology incorporated in the RAP*id* 4™ instrument in the areas of drug discovery and life sciences by Inverness Medical Switzerland GmbH (which is part of the Inverness Medical Innovations group of companies). As part of the wider deal, TTP LabTech has also acquired the design, manufacturing, and marketing rights to the RAP*id* 4 instrument, together with associated sensors and consumables, from Akubio Ltd.

Resonant Acoustic Profiling (RAP) is based on resonant quartz sensor technology optimised for the detection of molecular interactions. By directly detecting molecules bound to the surface of a quartz crystal, the system enables concentration measurement and analysis of the binding events between specific molecules in complex samples that may contain solvents, serum, growth media or other impurities. Currently, few technologies offer life scientists the ability to detect real-time kinetic data of this quality across such a broad range of samples, sample purity and sample concentrations.

RAP*id* 4™ is a flow-based analysis system which reduces the need to purify samples and generates accurate kinetic, affinity and concentration measurements from complex mixtures, such as blood, serum, cell culture supernatants and periplasmic extracts. A stand-alone, fully automated platform, RAP*id* 4 requires minimal user intervention and is controlled via user-friendly software, typically processing an average of 400 samples per day.



TTP LABTECH

## PRESS RELEASE

Says Dr Philip Blenkinsop, Managing Director of TTP LabTech “We are tremendously excited by the opportunities that this deal presents us with. RAP technology is highly complementary to our current Acumen range of fluorescence-based assay platforms and will enable our customers, both existing and new, to perform label-free interaction analysis on their development drugs. We also plan to use the technology to address markets which are new to us such as biotherapeutic development and protein expression analysis.”

Commented Dr Matt Cooper, Managing Director of Cambridge Medical Innovations Ltd (formerly part of Akubio Ltd and now a subsidiary of Inverness Medical Innovations Inc.): “TTP Labtech has a solid track record in the development and support of novel instrumentation for life sciences and drug discovery and is well positioned to commercialize the RAP•id 4 technology for these purposes, while at Cambridge and Inverness we continue to focus on our core missions of launching diagnostic products and the management of human health”

ENDS



# PRESS RELEASE

## **Editors' notes**

### **About TTP LabTech Ltd**

Based near Cambridge, UK, TTP LabTech is part of TTP Group plc, one of the world's most successful technology companies. TTP LabTech's mission is to provide practical and innovative solutions in the pharmaceutical and healthcare industries by combining the best science with first-rate engineering. TTP LabTech's products are designed to increase efficiency, effectiveness, flexibility or overall capability in key biopharmaceutical research processes including compound storage (comPOUND®), low volume liquid handling (mosquito®) and fluorescence detection (Acumen eX3).

For additional information on TTP LabTech, please visit [www.ttplabtech.com](http://www.ttplabtech.com).

### **About Inverness Medical Innovations**

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. A global leader in rapid point-of-care diagnostics, Inverness' products, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts.

For additional information on Inverness Medical Innovations, please visit [www.invernessmedical.com](http://www.invernessmedical.com)

### **About Cambridge Medical Innovations**

Cambridge Medical Innovations (CMI) is dedicated to developing products that will help in the diagnosis of diseases and enable the more efficient monitoring of human health. Our mission is to develop a series of diagnostic devices that can be sold worldwide. The company is located in Cambridge, UK.

For additional information on Cambridge Medical Innovations, please visit [www.cam-medical.com](http://www.cam-medical.com)